ASX Announcements

Update on trofinetide Phase 3 trial in Rett syndrome
Appendix 4C - quarterly
2019 year-end update and 2020 outlook
Patent to 2034 granted in Europe for Neuren's NNZ-2591
Phase 3 trial of trofinetide in Rett syndrome commences
Neuren Corporate Presentation, October 2019
Appendix 4C - quarterly
FDA grants Orphan Drug designation for NNZ-2591 in Phelan-McDermid and Pitt Hopkins syndromes
Pause in Trading
FDA grants Orphan Drug Designation for NNZ-2591 in Angelman